2022 ÇÏ°è ºÐÀÚÆó¾Ï¿¬±¸È¸ Àӻ󿬱¸ ¿öÅ©¼ó : 2022-08-27±³À°ÀÏÀÚ : 2022-08-27
±³À°Àå¼Ò : SC CONVENTION
±³À°ÁÖÁ¦ :
2022 ÇÏ°è ºÐÀÚÆó¾Ï¿¬±¸È¸ Àӻ󿬱¸ ¿öÅ©¼óÁÖÃÖ±â°ü : ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÐÀÚÆó¾Ï¿¬±¸È¸
´ã´çÀÚ : ±è¹Ì¼±
¿¬¶ôó : 02-575-3825
À̸ÞÀÏ :
katrd@hanmail.net ±³À°Á¾·ù : ³»°úÀÇÇб³À°, ±âŸ
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í »çÀüµî·Ï : 10000¿ø ÇöÀåµî·Ï : 20000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 13:10~13:35 Updated Progress of Korean EGFR Registry ¿©Ã¢µ¿(°¡Å縯ÀÇ´ë ³»°ú)
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 13:35~14:00 Research in Progress from a CRO Perspective ¹ÚÀçÀº(¾¾¾¾¾Ø¾ÆÀ̸®¼Ä¡)
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 14:00~14:25 Research in Progress in Data Management È«Á¤¼÷(ÇÁ·ÎÅ¥¶óƼ¿À)
ÈÞ½Ä 08-27 ¾Æ³ªÀ̽ºÈ¦ 14:25~14:40 Refreshment ()
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 14:40~15:05 Review of Ongoing Clinical Trials in Metastatic NSCLC °´ÙÇö(Ãæ³²ÀÇ´ë ³»°ú)
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 15:05~15:30 Review of Ongoing Clinical Trials in SCLC ¹Ú¼øÈ¿(°è¸íÀÇ´ë ³»°ú)
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 15:30~15:55 Review of Ongoing Clinical Trials in Stage III NSCLC ±èÄ¡¿µ(¿¬¼¼ÀÇ´ë ³»°ú)
ÈÞ½Ä 08-27 ¾Æ³ªÀ̽ºÈ¦ 15:55~16:10 Refreshment ()
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 16:10~16:35 First-line Platinum Doublet combined with Immune Checkpoint Inhibitor in patients with Metastatic NSCLC À̽ÂÇö(°æÈñÀÇ´ë ³»°ú)
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 16:35~17:00 First-line Platinum-Etoposide combined with Atezolizumab in Extensive-stage SCLC ¹Úµ¿¿ø(ÇѾçÀÇ´ë ³»°ú)
±³À°½Ã°£ 08-27 ¾Æ³ªÀ̽ºÈ¦ 17:00~17:25 Survival of Patients with NSCLC without Treatment ¾öÁß¼·(ºÎ»êÀÇ´ë ³»°ú)